Skip to main content

Breast Cancer Research and Treatment

Ausgabe 3/2024

Inhalt (20 Artikel)

Open Access Preclinical study

Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinoma

Saki Nakagawa, Minoru Miyashita, Ichiro Maeda, Atsushi Goda, Hiroshi Tada, Masakazu Amari, Yasuyuki Kojima, Koichiro Tsugawa, Yasuyo Ohi, Yasuaki Sagara, Miku Sato, Akiko Ebata, Narumi Harada-Shoji, Takashi Suzuki, Makoto Nakanishi, Tomohiko Ohta, Takanori Ishida

Open Access Preclinical study

Reciprocal regulation of forkhead box C1 and L1 cell adhesion molecule contributes to triple-negative breast cancer progression

Fan Zhang, Yue Xu, Jiediao Lin, Hongchao Pan, Armando E. Giuliano, Xiaojiang Cui, Yukun Cui

Open Access Preclinical study

Integrated analysis of diverse cancer types reveals a breast cancer-specific serum miRNA biomarker through relative expression orderings analysis

Liyuan Ma, Yaru Gao, Yue Huo, Tian Tian, Guini Hong, Hongdong Li

Clinical trial

Effectiveness and toxicity of five-fraction prone accelerated partial breast irradiation

Camille Hardy-Abeloos, Julie Xiao, Cheongeun Oh, David Barbee, Bhartesh Shah, Olivier Maisonet, Carmen Perez, Sylvia Adams, Freya Schnabel, Deborah Axelrod, Amber Guth, Nolan Karp, Oren Cahlon, Naamit Gerber

Clinical trial

Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome

Annemiek van Hemert, Ariane A. van Loevezijn, Anne Bosman, Carmen A. Vlahu, Claudette E. Loo, Marie-Jeanne T. F. D. Vrancken Peeters, Frederieke H. van Duijnhoven, Iris M. C. van der Ploeg

Open Access Clinical trial

Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer

Saumya Umashankar, Moming Li, Kaylee Blevins, Mi-Ok Kim, Melanie Majure, John Park, Laura A. Huppert, Michelle Melisko, Hope S. Rugo, Laura Esserman, A. Jo Chien

Open Access Clinical trial

The anti-proliferative effects of a frankincense extract in a window of opportunity phase ia clinical trial for patients with breast cancer

Ingrid V. Bonilla Valente, Denise Garcia, Andrea Abbott, Laura Spruill, Julie Siegel, Jessica Forcucci, George Hanna, Rupak Mukherjee, Mark Hamann, Eleanor Hilliard, Mark Lockett, David J. Cole, Nancy Klauber-DeMore

Clinical trial

The COVID-19 pandemic and its effects on follow-up of patients with early breast cancer: A patient survey

Ana-Alicia Beltran-Bless, Gail Larocque, Muriel Brackstone, Angel Arnaout, Jean-Michel Caudrelier, Denise Boone, Parvaneh Fallah, Terry Ng, Peter Cross, Nasser Alqahtani, John Hilton, Lisa Vandermeer, Gregory Pond, Mark Clemons

Clinical trial

Polypharmacy, over-the-counter medications, and aromatase inhibitor adherence in early-stage breast cancer

Elizabeth Joyce, Xueting Tao, Vered Stearns, Daniel F. Hayes, Anna Maria Storniolo, Kelley M. Kidwell, N. Lynn Henry

Clinical trial

Identification of patient subgroups who benefit from a behavioral intervention to improve adjuvant endocrine therapy adherence: a randomized-controlled trial

Emily A. Walsh, Kathryn Post, Katina Massad, Nora Horick, Michael H. Antoni, Frank J. Penedo, Steven A. Safren, Ann H. Partridge, Jeffrey Peppercorn, Elyse R. Park, Jennifer S. Temel, Joseph A. Greer, Jamie M. Jacobs

Epidemiology

Association between trajectories of prescription opioid use and risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors

Ching-Yuan Chang, Bobby L. Jones, Juan M. Hincapie-Castillo, Haesuk Park, Coy D. Heldermon, Vakaramoko Diaby, Debbie L. Wilson, Wei-Hsuan Lo-Ciganic

Open Access Epidemiology

Treatment patterns of patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitor-based regimens: a cohort study in the French nationwide healthcare database

Stephanie H. Read, Nadia Quignot, Raissa Kapso-Kapnang, Erin Comerford, Ying Zheng, Corona Gainford, Medha Sasane, Anne-Lise Vataire, Laure Delzongle, Francois-Clement Bidard

Open Access Epidemiology

Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial

Haiyun Wang, Douglas Yee, David Potter, Patricia Jewett, Christina Yau, Heather Beckwith, Allison Watson, Nicholas O’Grady, Amy Wilson, Susie Brain, Paula Pohlmann, Anne Blaes

Open Access Epidemiology

Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancer

Maria Eleni Hatzipanagiotou, Miriam Pigerl, Michael Gerken, Sophie Räpple, Verena Zeltner, Madeleine Hetterich, Peter Ugocsai, Elisabeth Christine Inwald, Monika Klinkhammer-Schalke, Olaf Ortmann, Stephan Seitz

Open Access Original Laboratory Investigation

Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer

Jianxin Zhong, Hanfang Jiang, Xiaoran Liu, Hao Liao, Feng Xie, Bin Shao, Shidong Jia, Huiping Li

Open Access Original Laboratory Investigation

Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies

Kelsey A. Fletcher, Mai H. Alkurashi, Andrew J. Lindsay

Brief Communication

Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors

Alexander S. Bang, Christopher J. Fay, Nicole R. LeBoeuf, Farshid Etaee, Jonathan S. Leventhal, Vincent Sibaud, Joshua Arbesman, Jennifer Y. Wang, Bernice Y. Kwong

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.